www.gelesis.comHealthcare / BioTech & PharmaFounded: 2006Funding to Date: $207.14MM
Gelesis is a biotherapeutics company advancing a novel hydrogel platform technology to treat obesity, help with weight management, and other chronic metabolic diseases.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/19/2020 | Series Growth 3 | $100.49MM | $xx.xx | $801MM | Hambro Perks, Vitruvian Partners | |
Price per Share
$xx.xx
Shares Outstanding
5,818,895
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.5x
Conversion Ratio
1.5x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Hambro Perks, Vitruvian Partners
|
||||||
02/28/2018 | Series Growth 2 | $30.37MM | $xx.xx | $215.68MM | Invesco Asset Management, Puretech | |
Price per Share
$xx.xx
Shares Outstanding
2,370,803
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Invesco Asset Management, Puretech
|
||||||
12/30/2015 | Series Growth | $31.5MM | $xx.xx | $181.84MM | Cormorant Asset Management, Invesco Asset Management, Priztker/Vlock Family Office, Puretech | |
Price per Share
$xx.xx
Shares Outstanding
2,538,274
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Cormorant Asset Management, Invesco Asset Management, Priztker/Vlock Family Office, Puretech
|
||||||
03/26/2015 | Series A-5 | $24.54MM | $xx.xx | $147.36MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
1,977,114
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
05/16/2014 | Series A-4 | $5.47MM | $xx.xx | $33.3MM | Priztker/Vlock Family Office, Puretech | |
Price per Share
$xx.xx
Shares Outstanding
1,450,529
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Priztker/Vlock Family Office, Puretech
|
||||||
01/03/2008 | Series A-2 | $3.03MM | $xx.xx | $21.45MM | Orbimed, Puretech Health, Qic Bioventures | |
Price per Share
$xx.xx
Shares Outstanding
1,161,254
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Puretech Health, Qic Bioventures
|
||||||
01/03/2008 | Series A-3 | $4.48MM | $xx.xx | $21.45MM | Orbimed, Puretech Health, Qic Bioventures | |
Price per Share
$xx.xx
Shares Outstanding
1,492,685
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Puretech Health, Qic Bioventures
|
||||||
01/03/2008 | Series A-1 | $7.27MM | $xx.xx | $21.45MM | Orbimed, Puretech Health, Qic Bioventures | |
Price per Share
$xx.xx
Shares Outstanding
1,636,971
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Orbimed, Puretech Health, Qic Bioventures
|